Atopic Dermatitis
Digital Education Hubs
CME Virtual Symposium / Webcasts
Session Slides
2021
New Pediatric Drugs
Biologics in Dermatology
Clinical Update: Novel Agents for the Long‐Term Management of Moderate‐to‐Severe Atopic Dermatitis
Current Landscape in the Treatment of Atopic Dermatitis
Tapinarof: Therapeutic AhR Modulating Agent (TAMA)
2020
Skin of Color Symposium
Challenging Cases in Atopic Dermatitis
Therapeutics on the Horizon
Recent Advances in Moderate to Severe AD: JAK Inhibitors
Navigating the Expanding Treatment Landscape for Pediatric Patients with Atopic Dermatitis
Elaine Siegfried, MD, who spoke on the live satellite symposium “Infants and Atopic Dermatitis” at the MOPD 2023 meeting, shares her expert advice for formulating a treatment plan and incorporating newer treatment options when managing pediatric patients with atopic dermatitis.
Questions:
- With recently expanded age indications for therapeutic agents to treat pediatric AD, what steps should clinicians consider when formulating a treatment plan for their younger patients?
- The treatment landscape for atopic dermatitis in pediatric patients has shown much growth over the past couple of years. How do you foresee the treatment landscape continuing to change in 2023?
- This was excellent, Dr Siegfried, thank you for your time. Is there anything else you’d like to add?
Podcast also available on:
Pearls for Early and Accurate Diagnosis of Infantile Atopic Dermatitis
Lawrence Schachner, MD, chair of the MOPD meeting and expert faculty who spoke on the live satellite symposium “Infants and Atopic Dermatitis”, shares clinical pearls for early and accurate diagnosis of atopic dermatitis in younger pediatric patients, as well as challenges often faced when assessing pediatric patients with skin of color.
Questions:
- Can you share your top pearls for early and accurate recognition of atopic dermatitis in infants?
- What gaps do you feel persist in the diagnosis and assessment of atopic dermatitis in infants, particularly those with skin of color?
- Thank you for your time today, Dr Schachner. This was fantastic. Is there anything else you’d like to add?
Podcast also available on:
Improving Communication and Shared Decision-Making with Caregivers of Patients with Atopic Dermatitis
Mercedes Gonzalez, MD, who spoke on the live satellite symposium “Infants and Atopic Dermatitis” at the MOPD 2023 meeting, shares clinical pearls for improving communication with patients and caregivers of patients with atopic dermatitis.
Questions:
- Caregivers often voice concerns regarding safety and side effects of newer systemic treatments for atopic dermatitis. What can clinicians do to better educate and reassure their patients and caregivers? How does shared decision-making factor into this?
- What gaps do you feel persist regarding the communication between clinicians and their patients/caregivers? What can clinicians do to address these gaps?
- Thank you for your time today, Dr Gonzalez. This was very informative. Is there anything else you’d like to add?
Podcast also available on:
Aug 11, 2022:
Peter Lio,
MD
The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis
Peter Lio, MD, LiVDerm faculty and atopic dermatitis expert, shares pearls from his session at the SBS 2022 event regarding the efficacy and safety of IL-13 inhibitors for treatment of AD.
- What factors should clinicians consider when selecting a biologic or systemic therapy to manage atopic dermatitis?
- Effectively and promptly diagnosing atopic dermatitis can be a bit tricky at times. What is your personal approach for effective diagnosis?
- Which patients would benefit most from an integrative approach to managing atopic dermatitis?
- How can clinicians execute effective shared decision-making strategies in the management of chronic skin conditions?
Podcast also available on:
Aug 17, 2022:
Christopher Bunick,
MD, PhD
Christopher Bunick, MD, PhD - August 11, 2022 - The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
- With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression?
- As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their patients?
- Atopic dermatitis is stated to impact several areas of a patient’s life, including the quality. How can clinicians best address this issue from a patient-centered perspective?
- What key takeaways should clinicians consider when constructing a management plan for chronic illnesses such as moderate to severe atopic dermatitis?
Podcast also available on:
Feb 17, 2022:
Brett King,
MD
A New Wave of Systemic Treatments: Atopic Dermatitis, Meet JAK
Brett King, MD, LivDerm faculty and pioneer in using Janus kinase (JAK) inhibitors for treating atopic dermatitis (AD) discusses the recent approvals of JAK inhibitors, selecting regimens for AD, and tips for managing AD with newer agents.
- There are several systemic and biologic agents for treating AD. What are your recommendations for including non-pharmacologic and at-home interventions alongside these newer systemic treatments?
- We now have two oral JAK inhibitors FDA approved for atopic dermatitis that clinicians can add to their toolbox. In your expert opinion, which AD patients are more likely to benefit from treatment with JAK inhibitor therapy?
- Compared to biologics, what are a few key differences that oral JAK inhibitors present regarding efficacy in treating AD?
- With all of the recent therapeutic breakthroughs, are there still any unmet needs in managing AD, and if so, what are they?
- Thank you so much for your time today, Dr King. This has been super informative. Is there anything else you’d like to add?
Podcast also available on:
Apr 9, 2021:
Lawrence Schachner,
MD
Atopic Dermatitis Therapy
Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:
- Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
- Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?
- How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?
Podcast also available on:
Apr 9, 2021:
Latanya Benjamin,
MD
Pediatric Skin of Color Symposium: Atopic Dermatitis
Latanya Benjamin, MD, shares clinical pearls about the management of atopic dermatitis in pediatric patients with skin of color, including:
- Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
- What is your personal approach to treating AD in pediatric patients with skin of color?
- Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
Podcast also available on:
Linda Stein Gold,
MD
Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis
Linda Stein Gold, MD, Chair of the CME Symposium “Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis” at SBS 2021, leads a panel discussion with Peter Lio, MD and Andrew Alexis, MD, to share clinical pearls and key takeaways about the management of atopic dermatitis.
Podcast also available on:
Fernanda Schmidt,
MD
Evolving Paradigms in Atopic Dermatitis
Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:
- What are the inside-out and outside-in mechanisms of AD?
- Is there a difference between these mechanisms across the age spectrum – from children to adults?
- Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?
Podcast also available on:
Leon Kircik,
MD
Perspectives on Emerging AD Therapies
Leon Kircik, MD discusses the potential role of emerging AD treatments, including:
- Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
- What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
- Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
- In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?
Podcast also available on:
Lawrence Schachner,
MD
Pearls on Integrating Newer AD Treatments
Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:
- How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
- Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
- How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?
Podcast also available on:
Neal Bhatia,
MD
The Promise of JAK Inhibitors in AD
Neal Bhatia, MD discusses the potential role of JAKis in AD, including:
- What changes would JAKis bring to the treatment of AD in the near future?
- What are some JAKis currently under clinical development for AD?
- Do you foresee that JAKis will play a role in both adult and pediatric AD?
- Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
- What are the long-term implications for dermatology practice?
Podcast also available on:
Patient Resources
Atopic dermatitis (AD), sometimes called eczema, is one of many allergic skin conditions that affects children and adults. AD is a chronic and often relapsing disease which presents as a dry, scaly rash that be accompanied by redness, itching, oozing, cracking or bleeding. People with AD are more likely to develop another atopic condition and are more prone to infections and mental health conditions. The management of AD involves keeping the skin clean and moisturized, eliminating irritants, using topical and oral medications, and avoiding flares and infections.
